FDA clears Novo's once-weekly Sogroya for kids with Turner Syndrome
Novo Nordisk's Sogroya just became the first and only once-weekly, long-acting growth hormone approved in the US for children 2.5 and older with growth failure tied to Turner Syndrome. The FDA nod, announced Nov. 20, hands families an alternative to years of daily injections. It's backed by the REAL8 trial, where weekly Sogroya grew kids at a comparable rate to daily shots.
- Original source: finance.yahoo.com.
- The source published it on Nov 20, 2026 at 8:47 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA approved once-weekly Sogroya (somapacitan-beco) injection for children aged 2.5 years and older with growth failure associated with Turner Syndrome, Novo Nordisk announced Nov. 20 from Plainsboro, N.J. The drug comes in 5 mg, 10 mg and 15 mg doses. It is the first and only once-weekly, long-acting growth hormone cleared for these children in the US.
Turner Syndrome is a chromosomal condition that affects development in females and commonly leads to short stature. Growth hormone treatment for these kids can stretch on for years, which makes the delivery method matter. Colleen Silk, Novo's group vice president for rare disease, said a once-weekly option means fewer injections across that journey. She called it a meaningful advancement in how the company supports growth in children with TS.
The approval rests on the pivotal REAL8 trial, which tracked 105 children with Turner Syndrome aged 2.5 and older for 52 weeks. Patients were randomized 2:1 — 68 got 0.24 mg/kg/week of once-weekly Sogroya, while 37 got once-daily somatropin at 0.05 mg/kg/day. Mean annualized height velocity at week 52 came in at 8.9 cm/year for Sogroya versus 9.7 cm/year for somatropin, an estimated treatment difference of -0.8 (95% CI: -1.58; 0.07).
The supportive secondary endpoint landed the same way: mean change in annualized height standard deviation score from baseline to week 52 was 0.77 for Sogroya and 0.86 for somatropin. Novo noted the daily somatropin dose used in the trial, 0.05 mg/kg/day, sits below the 0.067 mg/kg/day maximum approved for pediatric TS patients in the US.
With this indication, Sogroya now covers five growth-related conditions in children: growth hormone deficiency, Idiopathic Short Stature, Noonan Syndrome, short stature born Small for Gestational Age, and Turner Syndrome. It is also approved for adults with growth hormone deficiency.
TopicsNovo Nordisk · Sogroya · FDA · Colleen Silk · Turner Syndrome · somapacitan-beco · somatropin · REAL8
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science medtechdive.com 0 viewsZimmer files FDA 510(k) for Monogram knee robot, eyes 2027 launch
- Health & science phys.org Caught by @boxlink 1 viewYale team catches excitons acting like light in a one-atom-thick material
- Health & science wisbusiness.com 1 viewUW Alzheimer's tau tracer wins FDA approval after 2,200 scans
- Health & science hoodline.com 1 viewShionogi Snags Biotech Startup in Massive $2 Billion Rare Disease Power Play

